BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA
Links shared publicly online about this topic.
- 805total visits
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA
BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA" [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.
View full resource at news-medical.net
Tags: Genetic, Disease and Condition, Drug, Pharma, Baxter International, Glassia
Most Recently Shared on October 13, 2010 at 10:05 am By:
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA: BioRx, a specialty pharmacy company,... http://bit.ly/9n3jKH
Advertisement
